Procarbazine is a primary component of antineoplastic combination chemotherapy often used for the treatment of Hodgkin's lymphoma. It is believed that cytostatic and cytotoxic properties of procarbazine are mediated via its interaction with genomic DNA. Procarbazine is a carcinogen in animal models; it is classified as Group 2A compound by IARC. Also it is known as an in vitro and in vivo mutagen and genotoxicant. However, the molecular mechanism by which procarbazine induces mutations is not thoroughly understood and the spectrum of procarbazine-induced in vivo mutations is described insufficiently. We employed flow cytometry-based erythrocyte and T lymphocyte assays in order to quantify the frequencies of cells deficient in glycosylphosphatidyl inositol-anchored surface markers CD59 and CD48 (presumed mutants in the endogenous X-linked Pig-a gene) in rats. The rats were treated once daily with 100 mg/kg procarbazine HCl for 3 days. In addition, we sorted mutant-phenotype spleen T cells and immediately analysed their Pig-a gene using next generation sequencing of dual-indexed multiplex libraries and error-correcting data filtering. More than 100-fold increase in the frequencies of CD59-deficient RBCs was observed at Day 29 after the last administration, and a 10-fold increase in the frequency of CD48-deficient T cells was observed at Days 45 to 50. Sequencing revealed that, in T cells from procarbazinetreated rats, mutations in the Pig-a gene occurred predominantly at A:T basepairs when A was located on the non-transcribed DNA strand. A→T transversion was the most common mutation. Our results suggest that, at least for the transcribed X-linked Pig-a gene, in vivo methyl guanine adducts are not the major contributors to mutations induced by procarbazine.
Introduction
Procarbazine (Figure 1 ) is used in combination chemotherapy with vincristine, prednisone and mechlorethamine for treatment of Hodgkin's lymphoma and in combination with vincristine and lomustine for the treatment of certain brain tumors. Procarbazine is a known genotoxin. For mutagenicity, procarbazine requires metabolic activation (1) . For this reason, it sometimes produces ambiguous results in in vitro mutation detection models lacking appropriate metabolic functions. Procarbazine is specifically mentioned in the S2(R1) guideline of the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) as one of the compounds that are difficult to study in vitro; and the use of in vivo tests is recommended in the ICH guideline as a part of standard genotoxicity battery for safety evaluation. Procarbazine is a potent inducer of mutation in heterozygous Tk locus in L5178Y cell line in mouse lymphoma assay (MLA) in the presence of liver S9 fraction from aroclor-treated rats. In such conditions, procarbazine induces predominantly small colonies suggesting multi-locus deletions (2) .
However, the response is weak in the absence of S9. In the same cell line, procarbazine is a weak inducer of mutation in hemizygous X-linked Hgprt locus. Based on these observations, Clive and colleagues concluded that genotoxicity of procarbazine in MLA is mostly due to clastogenic or aneugenic mechanisms. Yet, procarbazine is not a clastogen in an in vitro micronucleus (MN) assay in human primary lymphocytes, regardless of the use of S9 in the assay.
While numerous studies have been published on in vivo mutagenicity and genotoxicity of procarbazine, only a few reports are available on the spectra of mutations induced by procarbazine in vivo. Most of the in vivo studies were performed with genetically engineered rodents using non-transcribed reporter transgenes (3) (4) (5) (6) (7) . A clear positive response in transgenic rodent assays suggests that procarbazine is a potent inducer of gene mutation in vivo. If this is correct, then in vivo assays utilising endogenous hemizygous X-linked genes [e.g. hypoxanthine guanine phosphoribosyl transferase gene (Hprt) or phosphatidyl inositolglycan class A gene (Pig-a)] as reporters of mutation should detect mutagenicity of procarbazine in non-transgenic rodents.
We employed recently described red blood cell (RBC) and T cell Pig-a assays (8) to investigate mutations induced by procarbazine in the rat. The assays are based on phenotypic detection of mutant cells deficient in protein markers anchored to the outer surface of cytoplasmic membrane by glycosylphosphatidyl inositol (GPI) anchor. The Pig-a gene is essential for biosynthesis of GPI anchor, a mutation in the single functional copy of the Pig-a gene renders the mutant cell deficient of GPI anchor and surface-bound GPI-anchored markers. The marker deficient mutants can be detected and enumerated by flow cytometry using immunofluorescent labeling of GPI-anchored markers with appropriate antibodies [reviewed extensively by Gollapudi et al. (8) ]. Multiple versions of in vivo flow cytometric Pig-a assays have been established for various species and various cell types. The RBC-based Pig-a assay is considered as animal friendly, sensitive and cost efficient tool for detecting potential mutagens, while the T cell-based Pig-a assay also allows determining the cause of marker deficiency at the level of genomic DNA or mRNA.
Studying procarbazine-induced mutation using the Pig-a assays should serve two goals: to further advance the methodology for error-free detection and characterisation of Pig-a mutant T cells using a modification of a recently described protocol for next generation sequencing (NGS) of dual-indexed multiplexed libraries (9) , and to determine the spectrum of procarbazine-induced mutations with improved accuracy and resolution in an endogenous gene. Overall, these data may provide clues to the mechanism by which procarbazine induces mutations in vivo.
Materials and methods

Animals and treatment
All animal procedures were performed at Covance Laboratories; the procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Covance Laboratories. Outbred Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA). Animals were allowed to acclimate for approximately 1 week before starting the treatment. Water and food were available ad libitum throughout the acclimation and experimental period. Each treatment group consisted of six randomly selected rats, 6-8 weeks of age at the start of the treatment. Procarbazine HCl purchased from Sigma-Aldrich was formulated in 0.9% saline at concentration of 10 mg/ml. Animals were administered intraperitoneally (i.p.) 0 or 100 mg/kg/day procarbazine HCl for three consecutive days (Days 1, 2 and 3).
RBC Pig-a assay
The frequencies of CD59-deficient reticulocytes and total RBCs were determined in the peripheral blood collected on Day 29 using MutaFlow Rat kit from Litron Laboratories (Rochester, NY). Blood labeling and analyses on FACS Canto II (BD BioSciences, Milpitas, CA) flow cytometer were performed on the day of blood collection following instructions from the manufacturer of the MutaFlow kit.
T cell Pig-a assay and sorting
Spleens from control and procarbazine-treated rats were shipped from Covance Laboratories to National Center for Toxicological Research (NCTR) in RPMI1640 medium (Gibco/Invitrogen, Grand Island, NY) on wet ice by express carrier overnight. Upon arrival to NCTR, spleen from each animal was divided into four to five equal pieces (depending on the overall size of the spleen); nucleated cells released from four pieces of spleen were combined and depleted from RBCs by centrifugation on lympholyte-R density gradient (Cedarlane, Burlington, NC) followed by treatment with RBC lysis buffer (BioLegend, San Diego, CA) as described previously (10) (11) (12) . The fraction of T cells deficient in surface-bound GPI-anchored CD48 marker (presumptive Pig-a mutants) was determined by labeling an aliquot of purified white blood cells with anti-rat CD48 antibody (clone OX-45) conjugated with phycoerythrin (PE) and anti-rat T cell receptor (TCR) α/β antibody (clone R73) conjugated with allophycocyanin (APC) (both antibodies were purchased from BioLegend, San Diego, CA; PE anti-CD48 was available from BioLegend as a custom order) and with viability stain 7AAD (BD Biosciences). The labeled samples were analysed on a FACSAria IIIU flow cytometer/sorter (BD BioSciences, Milpitas, CA). Gating strategy for analysis and sorting of T cells is shown in Figure 2 . T cell mutant frequency was determined as a ratio of [TCR + CD48 − ]/ [TCR + ] among 7AAD-negative viable cells. For sorting, the above antibody labeling reaction was scaled up 20×, and CD48 + wild-type cells were depleted from the samples by conjugating with anti-PE magnetic beads and processing on two LS columns (one half of the scaled up labeling reaction on each column) mounted on a Quardo MACS magnet (all from Miltenyi Biotec, Auburn, CA). The samples enriched for CD48-deficient cells were mixed with 7AAD and processed for bulk sorting on FACSAria sorter; cells were sorted into a 0.2-ml tube filled with 100 μl of DNAzol Direct (MRC, Cincinnati, OH) using single-cell purity sorting mode. Approximately 1000 CD48-deficient cells were sorted from the magnetically enriched samples. 1000 CD48 + wild-type T cells were sorted from an unenriched labeled sample. 
Mutation analysis with multiplexed libraries (MAML)
Cells sorted into DNAzol Direct were gently pipetted to release genomic DNA. The suspension of genomic DNA from all 1000 cells was used to make 60 aliquots each containing approximately 10 genomes (i.e. 1 μl of the sorted cells). Each 10-genome aliquot was used to amplify three fragments of the Pig-a gene in a multiplex reaction using Encyclo PCR kit (Evrogen; Moscow, Russia) and three pairs of external primers (each primer at a final concentration of 250 nM) in a volume of 16 μl using the following temperature profile: 95°C × 2 min 30 s + (95°C × 30 s + 58°C × 30 s + 72°C × 2 min) × 40. Then the products of the first round multiplex reactions were diluted and used as a template in three separate reactions each amplifying one fragment of the Pig-a gene with a pair of internal primers in a final volume of 16 μl using Encyclo PCR kit and each primer at a final concentration of 250 nM. The resulting products of nested PCR were analysed on 1% agarose gels. Then the nested PCR products belonging to each aliquot were combined in one tube and used for preparing mini tagged libraries for NGS. One microliter of each fragment mixture (~1 ng) was combined with 0.25 μl of enzyme and 1.25 μl of buffer from Nextera DNA library Prep kit (Illumina, San Diego, CA) and incubated for 10 min at 55°C to shear the amplified Pig-a fragments into smaller pieces. Unique combinations of P5 and P7 indexed adapters (based on Illumina's Nextera XT Index v2 published sequences), each at 250 nM final concentration, were added to the ends of sheared fragments in a 25-μl PCR reaction using reagents from the Encyclo PCR kit and the following temperature profile: 72°C × 3 min + 95°C × 5 min (95°C × 30 s + 58°C × 30 s + 72°C × 30 s) × 8 + 72°C × 5 min. The resulting individual dualindexed libraries were pooled into one tube and purified on one column from QiaQuick PCR purification kit (Qiagen). Short fragments were eliminated from the combined library by passing through a column from GeneRead Size Selection kit (Qiagen). The complete dualindexed library was analyzed on a 2100 Bioanalyzer and quantitated using a High Sensitivity DNA kit (both from Agilent, Santa Clara, CA). Sequencing was performed on Illumina NextSeq 500 using Mid Output 150-cycle kit (Illumina) with paired-end sequencing using dual indexing protocol.
NGS data analysis
The reads generated in the sequencing protocol were collated by unique indices and saved as fastq files. The collated reads were mapped to the three reference rat Pig-a genomic sequences (corresponding to the amplified #2, #3 and #4 fragments of the rat Piga gene) using BWA software mem algorithm (13) . BWA aligner is available for downloading from http://bio-bwa.sourceforge.net/. The reference sequences were derived from the UCSC Genome Browser (14) for rat genome version Rn5, chrX, in reverse complement: from 32169495 to 32171022 for fragment #2 (1528 bp), from 32163585 to 32165236 for fragment #3 (1652 bp), and from 32160092 to 32161500 for fragment #4 (1409 bp); the sequences can be downloaded from https://genome.ucsc.edu/ or elsewhere. Mutations were called using LoFreq, an algorithm specifically designed to detect lowfrequency mutations from NGS data (15) . LoFreq is available for downloading from http://csb5.github.io/lofreq/. First, the mapped reads were processed using the 'lofreq viterbi' command. Then the aligned reads were sorted by base position relative to reference sequence using the 'samtools sort' command of the SAMtools software (available at http://samtools.sourceforge.net/). Then the sorted reads were processed by the 'lofreq indelqual' command to enable calling small insertions and deletions. Finally, variants with frequencies greater than 5% in an individual dual-indexed mini library (and the corresponding 10-genome aliquot of sorted T-cells) were called by LoFreq (using the 'lofreq call' command) into separate variant call format (VCF) files. Variants encountered in at least two 10-genome aliquots derived from the same rat were considered as mutations. Variants identified only in one aliquot (out of 60 analyzed for each animal) were not considered as true mutations.
Results
Acute treatment of rats with three consecutive daily i.p. injections of 100 mg/kg procarbazine resulted in significant increases of mutant phenotype RBCs and spleen T cells (see Table 1 ). The frequency of mutant reticulocytes and total RBCs measured on Day 29 was approximately 100-fold higher in procarbazine-treated animals than in control animals. The average frequency of mutant T cells in treated animals was approximately 10-fold higher than in vehicle-control animals. Based upon the number of sorted mutant-phenotype T cells from a known fraction of the spleen, the total number of CD48-deficient spleen T cells in each procarbazine-treated animal was estimated to exceed 2 × 10 3 (although only 1000 cells were sorted for MAML; and from these ~600 cells were analyzed by NGS). Identification of Pig-a mutant T cells using flow cytometry, magnetic enrichment of spleen cell samples for CD48-deficient T cells and sorting were performed as previously described (10) (11) (12) , except that for sorting of mutant T cells a larger gate was used than the gate determined with the mutant-mimic control sample (see Figure 2) . The population of CD48-deficient Pig-a mutant T cells was distinct and separate from wild-type cells for the samples derived from all procarbazine-treated rats.
Mutations in sorted T cells were analyzed using MAML approach outlined in Figure 3 . Pig-a mutations were identified in pools of genomic DNA from approximately 10 sorted cells. The aliquoted DNA was used for amplification of three fragments off the X-chromosomes containing Pig-a coding sequence. Expected Pig-a fragments failed to amplify from 3 to 20% of aliquots. The successfully amplified fragments for each aliquot were uniquely tagged and sequenced using Illumina NGS chemistry and instrumentation.
A total 24, 26 and 31 independent Pig-a mutations were found among ~600 CD48-deficient analyzed T cells derived from Rats #13, 17 and 18, respectively (see Figure 4) . Mutations potentially affecting expression of the Pig-a function were found in the population of sorted CD48-deficient T cells. These included mutations causing amino acid changes in the protein sequence and mutations at donor/acceptor sites of the Pig-a gene affecting mRNA splicing. One mutation in Rat #13 was identified in the untranslated 3′ region of the Pig-a gene (base 1111 of fragment #4); one mutation in Rat #17 was found inside the first intron of the gene near the beginning of exon 2 (proximal to the canonical AG 2-base acceptor splice site). The majority of identified Pig-a mutations were single base-pair substitutions, only a few base-pair insertion mutations were found. Four mutations (one in Rat #13 and three in Rat #18) were called complex as they were two separate base-pair substitutions mutations (or an insertion and a substitution) separated by 1 to 10 base-pairs. The spectrum of determined procarbazine-induced Pig-a mutations is shown in Table 2 . The majority of the identified independent mutations in procarbazinetreated animals accounting for over 60% of all mutations were A→T and A→C transversions, when A was present on non-transcribed strand of the Pig-a gene.
By averaging the mutation frequencies associated with each mutation from each PCR reaction from the same animal (or pool of mutants), the overall mutation frequencies for every mutation can be derived. Additionally, by aggregating all the resulting mutation frequencies for all mutations in each animal (or pool of mutants), the overall number of mutants present in each sort/pool can also be derived. In this manner, we estimate that, on average, 75% of sorted CD48-deficient cells from procarbazine-treated animals had mutations in the Pig-a gene within the areas of the gene covered by our sequencing strategy. Such an estimate does not assume that homologous areas/fragments of the Pig-a gene of different sorted cells amplified equally efficiently (or inefficiently) in multiple PCRs employed in the MAML protocol, but instead relies on the mutation frequencies reported for each mutation in every PCR reaction. Since we count as bona fide mutations only those that were found in more than one 10-genome aliquot (out of 60), it is conceivable that legitimate non-expanded rare unique mutations are unaccounted for. Therefore, the frequency of mutants among the sorted cells may exceed the calculated 75%. On the right side, mutations within specific fragments are identified by position within the corresponding fragment and the sequence change. Solid color squares represent mutation found in all aliquots; these mutations are deemed to be germline polymorphisms. Fewer than 60 aliquots are shown for each animal as some aliquots failed to amplify DNA fragments of expected side (these aliquots were not analyzed by NGS). For example in Rat #13, 58 aliquots were analyzed by NGS; in the first aliquot, mutations were found in positions 872 of fragment #2 (A>G, open square, amino acid change Tyr>Cys) and in position 1364 of fragment #2 (T>A, solid square; this mutation was present in all aliquots and in liver DNA, a suspect germline polymorphism); for Rat #13, mutation in position 872 of fragment #2 was found in 22 aliquots. All identified potential polymorphic sites (solid squares) are outside the coding region of the Pig-a gene (i.e. in introns). Highlighted with gray on the right are complex mutations: two base-pair substitutions or one base-pair substitution and a frameshift occurred close to each other (tandem mutations, separated by less than 10 bases). Mutations 1111 of fragment #4 found in Rat #13 and 444 of fragment #2 found in Rat #17 are far outside Pig-a open reading frame (could be potential artifacts of MAML). Mutations at positions 147 and 149 of fragment #3 found in Rat #17 are within eight bases from the intron-exon junction, these could potentially affect the corresponding splice acceptor sequence. All other identified mutations either resulted in legitimate amino acid substitutions in the Pig-a protein sequence, frameshifts, premature translation terminations or affected one of the two bases of splice sites proximal to intron-exon junction.
In the population of sorted CD48 + WT T cells (from the procarbazine-treated Rat #13), no Pig-a mutations were found using the criterion for calling a mutation only if it is found in two separate aliquots.
Of interest, in Rats #13 and 17 a polymorphic sequence (different from the reference sequence) was identified in the second intron of the Pig-a gene (between exons 2 and 3) fairly remote from splice sites (T>A substitution at base 1364 of fragment #2). In Rat #18, three polymorphic sites were found in different positions: one was found inside the first intron (A>G substitution as base 262 of fragment #2), the second one was found in intron 2 proximal to exon 2 (a four-base deletion at base 1416 of fragment #2), and the third one was found in intron 2 proximal to exon 3 (an insertion of T at base 101 of fragment #3). These polymorphic sequences were detected in all aliquots of sorted cells analyzed for each specific rat. Subsequently, the polymorphisms were confirmed as germline-transmitted in all three animals by sequencing liver Pig-a genomic DNA from these rats (data not shown). It remains to be determined how often such polymorphisms can be found in Sprague-Dawley rats or in rats of other lineages and how it may affect the performance of the Pig-a assays.
Discussion
The goals of this study were to measure the response to procarbazine treatment in the endogenous X-linked Pig-a gene in hematopoietic cells and to determine the mutational signature of procarbazine in the Pig-a gene of rat peripheral T cells. The rodent RBC-based Pig-a assay is a well-established tool for detecting potential mutagens. In fact, the mutagenicity of procarbazine has been previously studied using RBC Pig-a assay in the mouse with acute doses of up to 150 mg/kg/day for three consecutive days (16) . In that mouse study, procarbazine was a robust genotoxicant, as was evidenced by a 29-fold induction of micronucleated reticulocytes in high dosetreated mice, but the mutagenicity of procarbazine was relatively weak. While the frequency of Pig-a mutant reticulocytes in total RBCs in treated mice were significantly increased compared to the untreated animals, the absolute Pig-a mutant frequency values were rather low in procarbazine-treated mice (<7 × 10 -6 for reticulocytes and <5 × 10 -6 for total RBCs at all evaluated time-points). Pletsa and colleagues studied the mutagenicity of procarbazine in the transgenic Muta™Mouse model and observed a robust 16-fold increase in the number of mutant plaques at a cumulative dose of 1000 mg/ kg delivered to mice in five equal daily administrations (6) . In our study with Sprague-Dawley rats, the mutagenic effect of procarbazine was greater than what was determined in mice. For instance, more than a 100-fold increase in the total RBCs Pig-a mutant frequency in our study was greater than the maximal 16-fold increase in LacZ transgene mutant frequency in the Pletsa et al. (6) study, higher than a 30-fold increase determined by Myhr (5) , and higher than a 12-fold increase reported in a Japanese collaborative study (7) . In addition, the average absolute frequency of Pig-a mutant total RBCs of ~133 × 10 -6 in our study was higher than ~5 × 10 -6 mutant frequency observed by Phonethepswath et al. (16) . The reasons for such a difference in the induction of Pig-a mutation in response to treatment with procarbazine in rats and mice is not clear. Perhaps, in the Phonethepswath et al. (16) study, an earlier less sensitive version of the mouse total RBC Pig-a assay was used. A more refined and validated protocol is currently recommended by Litron, the manufacturer of the mouse MutaFlow total RBC Pig-a kit. To the best of our knowledge, no results of mechanistic studies of procarbazineinduced somatic mutation in rats have been published previously. The results reported in this study and by various other groups demonstrate that, in vivo, procarbazine exhibits a substantial gene mutation and clastogenicity potential, whereas it is predominantly a clastogen in vitro. Together, these observations suggest that measuring in vivo gene mutation (e.g. using the RBC Pig-a assay where appropriate) could be beneficial in routine nonclinical safety evaluations because it may inform more accurately on the overall risk associated with compounds of interest.
Using a T cell Pig-a assay in mutagenicity studies has a distinct advantage: T cells have genomic DNA and mRNA which may allow determining the linkage between the detected mutant phenotype (CD48-deficiency) and the actual mutation in the Pig-a gene. Previously, Pig-a mutations have been demonstrated in clonally expanded mutant-phenotype T cells derived from rats treated with powerful mutagens, such as DMBA and ENU (10, 11) . Since clonal expansion is only 10-20% efficient (which is typical for primary cell cultures), up to 90% of individually sorted CD48-deficient spleen T cells do not develop into clones and cannot be analyzed. If the laborious and inefficient cloning step could be avoided, then more cells could be analyzed by sequencing and provide more accurate spectra of mutation induced by compounds of interest in a shorter time-frame. Ideally, individual mutant-phenotype cells should have been analyzed by sequencing in our study, but this would present significant technical challenges. It is difficult to consistently amplify multiple fragments using a single DNA molecule as a template (e.g. a single copy of X-linked Pig-a gene in male cells). Also, while sorting of single cells is a fairly well established methodology (especially when sorting into 200 μl of culture medium in 96-well plates), sorting of individual cells into small volumes (e.g. sorting into 1 μl of cell lysis buffer) is not as efficient because sorted cells may deposit themselves on the walls of the well (and dry out) rather than hitting the small cross-section of a 1-μl droplet (perhaps, less than 1 mm 2 ) at the bottom of the well. A more efficient process may be sorting cells (e.g. up to 1000) into a larger volume of lysis solution (e.g. Table 2 . Spectrum of independent Pig-a mutations in CD48-deficient sorted spleen T cells derived from procarbazine-treated rats
Animal
Types of mutations relative to non-transcribed strand of the Pig-a gene Mutations found A>T A>C A>G T>A T>C T>G C>A C>T C>G G>A G>T G>C Ins Cplx   13  7  6  2  0  2  2  0  3  0  1  0  0  0  1  24  17  12  3  6  0  2  1  0  0  0  1  0  0  1  0  26  18  15  6  4  0  0  0  0  0  0  2  0  0  1  3  31  Total in three animals  34  15  12  0  4  3  0  3  0  4  0  0  2  4 81 Fraction of total (approx.) 42% 19% 15% 0% 5% 4% 0% 4% 0% 5% 0% 0% 2% 5%
Potential germline polymorphisms are not counted as procarbazine-induced mutations. Cplx, complex mutations (with more than one nucleotide altered); Ins, insertion mutations.
100 μl, with the cross-section of ~20 mm 2 ), and then processing smaller aliquots containing genomes of several cells. Using such an approach, more sorted cells may become available for sequencing. As DNA from several different mutants is most likely present in each aliquot, solid state sequencing (that operates at the level of individual DNA molecules) should be used to analyze mutants in the mixture.
For practical purposes, the templates for amplification and subsequent sequencing present in aliquots will still be single copies of the mutated Pig-a genes. This means that there will be a chance for generating false Pig-a mutations as random errors made by Taq polymerase in early cycles of amplification reactions. In vivo clonal expansion of mutants is common, as was observed in our previous Pig-a and Hprt studies (10, 11) . As a result, a condition was imposed for calling true mutations in MAML: they should be detected in more than one aliquot. Such a restriction may eliminate poorly expanded mutants in vivo, but it should also filter out randomly distributed Taq errors, as it is unlikely that identical polymeraseintroduced errors will happen at the same base of two or more copies of the Pig-a gene that originated from different mutant cells. Our choice of analyzing 10 genomes per aliquot and the redundancy in calling mutation was a reasonable compromise in efficiency versus accuracy for detecting mutations. Without redundancy, in the sample of 1000 sorted CD48 + wild-type T cells from Rat #13, several of what we believe false mutations would be identified. With redundancy, no mutations appear in sorted CD48-proficient T cells, and the vast majority of the identified mutations in CD48-deficient T cells are legitimate mutations, likely affecting (ablating) Pig-a function. Only two mutations detected within the surveyed regions of the Pig-a gene, T>C at base 1111 of fragment #4 in Rat #13 and A>T at base 444 of fragment #2 in Rat #17, do not appear to obviously impact the expression of the Pig-a function. These two could be rare artifacts of the overall analysis approach, consequences of error-prone Taq polymerase. On the other hand, one of these mutations (specifically in Rat #17) occurred in a sequence that is consistent with a consensus splice acceptor site. There is some ambiguity where exactly the second exon of Pig-a starts. It is conceivable that, if the second exon begins further into the 5′ end, then mutation at 444 of fragment #2 may disrupt mRNA maturation and inactivate Pig-a function. It is still not clear how a base-pair substitution at 1111 of fragment #4 (3′-distant from the normal stop codon of the Pig-a gene) can negatively affect the expression of Pig-a gene, unless it happens at or near polyadenylation signal sequence. But where such a signal sequence is within the Pig-a transcript remains unclear.
It must be mentioned here that MAML is not intended to detect large partial or complete gene deletion mutations. Also, the mutations occurred outside the monitored fragments #2, #3 or #4 are not identifiable with our approach. It is conceivable that a certain number of wild-type T cells could be sorted as mutants (e.g. due to cytometer errors or shear proximity of the mutant sorting gate to wild-type population on the flow cytograms). The fraction of such 'unidentifiable' mutants in our sorted sampled was estimated to be fairly low, 10-30%, and consistent with the previous estimates of such mutants in animals treated with ENU and DMBA (10, 11) .
According to our approach, the spectrum of procarbazineinduced mutations is dominated by A>T and A>C transversions when A is on non-transcribed DNA strand, which is an unexpected finding. In vivo, procarbazine readily forms detectable O 6 -meG and 7-meG adducts and causes depletion of the endogenous DNA repair enzyme methylguanine DNA alkyltransferase (17) (18) (19) (20) . Based on this data, procarbazine was assumed to induce mutations predominantly at guanine bases of DNA, forming mostly G:C>A:T transitions via direct miscoding mechanism of O 6 -meG. On the other hand, the limited sequencing data of in vivo mutations induced by procarbazine indicate that this type of mutation is not common. In LacZ transgenic mice treated with procarbazine, most G:C>A:T transitions occurred at CpG sites, which suggests procarbazine-independent deamination of endogenous 5-meC (6) . Most CpG sites in untranscribed transgenic reporter genes are believed to be methylated in vivo. If these mutants are excluded, then the spectrum of procarbazine-induced mutations would have mutations predominantly at A, with A:T>T:A being the most frequent among base-pair substitutions. Unfortunately, the published data in transgenic animals is rather rudimentary, based upon too few sequenced mutants. We have identified many more independent mutants (total of 81) in the endogenous Pig-a gene that is supposed to be actively transcribed and unmethylated at CpG sites. In our study, G:C>A:T transitions in the Pig-a gene represent less than 10% of all mutations and are not obviously biased toward transcribed or non-transcribed strands. Pletsa et al. mention that procarbazine forms N 3 -meA adducts and facilitates production of various free radicals. Perhaps there are other metabolites of procarbazine that form bulky adducts at A. N 3 -meA and those yet unidentified DNA lesions might be responsible for majority of mutations determined in our study. In many ways, the spectrum of procarbazine-induced mutations in the Pig-a gene resembles the spectrum of DMBA-induced Pig-a mutations in lymphocytes, most mutations are at As on the non-transcribed DNA strand (10, 21) . The difference is that there were no G>T mutations in procarbazinetreated rats but in DMBA-treated rats these accounted for 15% of the overall mutants. It would be interesting to compare the spectrum of mutations induced by procarbazine in this study with mutations induced in another endogenous X-linked gene, the Hprt gene. To our knowledge, such information is not available in the literature.
In conclusion, we have confirmed that procarbazine is a powerful in vivo mutagen. It induces hematopoietic cells that are deficient in GPI-anchored markers. The mutant-phenotype cells can be detected using flow cytometry-based RBC and T cell Pig-a assays. In T lymphocytes, procarbazine induces mostly transversions and transitions at A's, with the mutated A on non-transcribed strand; all other mutations are present in minor fractions. Our approach for analysis of Pig-a mutation in small pools of cells using NGS is useful for validating the mutant phenotypegenotype link in cell types for which clonal expansion techniques are not available (e.g. for rat bone marrow nucleated erythroid cells or granulocytes).
